2019 Outlook - Planned Pipeline Milestones
ADVM-022 for wet AMD: Provide an update on enrollment from the OPTIC phase 1 clinical trial in H1 2019
Provide interim data on the three cohorts from the OPTIC phase 1 clinical trial by Q1 2020
Rare Disease Program: Provide an update preclinical development plan in H1 2019
Financial Guidance : Adverum’s cash, cash equivalents and marketable securities were $217.9M as of September 30, 2018. Adverum expects this quarter-end cash position to fund operations at least through H1 2020.
Subscribe for full text news in your inbox